iRhythm reports Q2 EPS (61c), consensus (89c)

Reports Q2 revenue $148M, consensus $146.21M. “The second quarter of 2024 was another quarter of continued traction in our core markets reflective of record demand for Zio products and services,” said Quentin Blackford, president and CEO of iRhythm. “Second quarter revenue growth of 19.3% year-over-year was driven by continued uptake from new accounts opened in the prior twelve months but also expansion of the ambulatory cardiac monitoring market by pushing deeper into primary care channels. Zio’s value proposition to address the quintuple aim of healthcare is clearly resonating with providers in integrated delivery networks as well as large, national primary care accounts. This strength in our core market has given us confidence to raise our revenue guidance and profitability targets for the full year.”